Nasdaq:APLS
Apellis Pharmaceuticals, Inc.
A Nasdaq-listed biotech firm commercializing immunology therapies for sight-threatening eye diseases and rare conditions with a recent path to profitability.
Key Metrics
Investment Thesis
Bull Case
Investors may favor Apellis due to its successful commercialization track record which has led to a historic revenue expansion and recent transition to net income positivity. The company's proprietary immunology platform offers a clear path for future growth through multiple late-stage clinical programs targeting high-value indications in ophthalmology and rare diseases.
Bear Case
Potential buyers should be wary of the company's historically large retained earnings deficit of $3.01B, which indicates a prolonged period of heavy investment that requires careful monitoring to ensure sustainable operations. Despite recent profitability, the stock remains exposed to the high attrition rates typical of biotech development and potential volatility in cash flows if commercial sales growth slows.
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals is a biotechnology company developing proprietary immunology-based therapies for acute and chronic eye diseases and rare disorders. The company's portfolio includes approved products like APL-2 (aplespimod) for retinal vein occlusion and various investigational candidates in development across ophthalmology and rare disease markets.
Analysis
Management Discussion
Financial performance has improved dramatically with revenue surging from $75.4M in 2022 to $1.00B in 2025, driven by strong commercial adoption of approved therapies and successful scale-up of operations. The company achieved a net profit of $22.4M in the latest year, marking a significant turnaround from historical losses while maintaining robust cash reserves of $467.8M to fund continued R&D efforts.
Industry Overview
The ophthalmology and rare disease sectors are experiencing rapid innovation driven by advances in immunology and gene therapy, creating significant opportunities for companies with differentiated assets. However, these markets are becoming increasingly competitive as major pharmaceutical players expand their portfolios into sight-threatening conditions and underserved patient populations.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $75.4M | $396.6M | $781.4M | $1.00B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $75.4M | $396.6M | $781.4M | $1.00B |
| Operating Expenses | $670.0M | $913.7M | $946.3M | $948.4M |
| Operating Income | $-594.6M | $-517.1M | $-165.0M | $55.4M |
| R&D | $387.2M | $354.4M | $327.6M | $295.9M |
| G&A | $277.2M | $500.8M | $501.1M | $550.3M |
| Stock-Based Comp | $91.1M | $105.9M | $114.1M | $104.0M |
| Depreciation | $1.6M | $1.8M | $1.8M | $1.6M |
| Other OpEx | $5.6M | $58.5M | $117.7M | $102.2M |
| Non-Operating Income | $-56.9M | $-9.4M | $-31.7M | $-31.3M |
| Pre-Tax Income | $-651.5M | $-526.5M | $-196.7M | $24.1M |
| Income Tax | $669.0K | $2.1M | $1.2M | $1.7M |
| Continuing Ops | $-652.2M | $-528.6M | $-197.9M | $22.4M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-652.2M | $-528.6M | $-197.9M | $22.4M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-652.2M | $-528.6M | $-197.9M | $22.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $719.5M | $766.3M | $789.0M | $1.01B |
| Cash & Equivalents | $551.8M | $351.2M | $411.3M | $466.2M |
| Accounts Receivable | $7.7M | $206.4M | $264.9M | $366.2M |
| Inventory | $85.7M | $146.4M | $81.4M | $142.6M |
| Prepaid Expenses | — | — | — | $38.3M |
| Other Current Assets | $74.3M | $62.3M | $31.3M | $1.5M |
| Long-Term Assets | $40.7M | $22.4M | $96.1M | $60.4M |
| PP&E (Net) | $6.1M | $4.3M | $3.0M | $1.7M |
| Operating Leases | $18.7M | $16.7M | $16.1M | $18.2M |
| Other LT Assets | $15.8M | $1.3M | $77.1M | $40.5M |
| Total Assets | $760.2M | $788.7M | $885.1M | $1.08B |
| Current Liabilities | $167.6M | $247.6M | $185.5M | $323.6M |
| Accounts Payable | $37.3M | $37.5M | $38.6M | $56.8M |
| Current Leases | $5.6M | $6.4M | $6.8M | $7.1M |
| Other Current Liab | $29.5M | $75.8M | $0 | $93.7M |
| Long-Term Liabilities | $422.7M | $346.6M | $471.0M | $381.5M |
| LT Operating Leases | $14.4M | $11.5M | $10.2M | $11.9M |
| Other LT Liab | $408.4M | $335.2M | $460.8M | $369.6M |
| Total Liabilities | $590.3M | $594.2M | $656.5M | $705.1M |
| Shareholders' Equity | $169.9M | $194.5M | $228.5M | $370.1M |
| Paid-In Capital | $2.48B | $3.04B | $3.27B | $3.39B |
| Retained Earnings | $-2.31B | $-2.84B | $-3.04B | $-3.01B |
| AOCI | $-875.0K | $-3.5M | $-3.3M | $-2.1M |
| Total L&E | $760.2M | $788.7M | $885.1M | $1.08B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-652.2M | $-528.6M | $-197.9M | $22.4M |
| Non-Cash Adjustments | $98.0M | $-336.5M | $53.5M | $-149.4M |
| Working Capital Changes | $40.5M | $270.4M | $56.6M | $172.3M |
| Cash from Operations | $-513.7M | $-594.7M | $-87.9M | $45.3M |
| Capital Expenditures | $1.5M | $773.0K | $403.0K | $313.0K |
| Cash from Investing | $59.9M | $-674.0K | $-403.0K | $-313.0K |
| Cash from Financing | $365.7M | $394.5M | $149.2M | $8.9M |
| FX Effect | $-488.0K | $135.0K | $-659.0K | $1.2M |
| Net Change in Cash | $-88.7M | $-200.8M | $60.3M | $55.1M |
| Beginning Cash | $641.8M | $553.1M | $352.3M | $412.6M |
| Ending Cash | $553.1M | $352.3M | $412.6M | $467.8M |
Frequently Asked Questions
How does Apellis Pharmaceuticals, Inc. make money?
The company operates primarily through its commercialization of approved ophthalmology products such as APL-2 for retinal vein occlusion, alongside significant revenue contributions from ongoing clinical development programs targeting acute macular degeneration and rare immunologic disorders.
What are the main risks for APLS?
The company faces high reliance on the success of its clinical trials for investigational products, where failure could impact future growth prospects and stock valuation. As a biotechnology firm, Apellis is subject to strict regulatory scrutiny and potential patent challenges that could affect product exclusivity and market share. The transition from cash burn to profitability may face headwinds if commercial uptake of new assets lags or if competition increases in the ophthalmology sector.
What is APLS's competitive advantage?
Apellis possesses a proprietary pipeline focused on novel immunomodulatory mechanisms that offer differentiated treatment options where standard-of-care options are limited. The company has established a strong commercial presence in the ophthalmology space with regulatory approvals for its lead asset, providing immediate cash flow while developing future revenue streams.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.